A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of BC2027 in Patients With Advanced Solid Malignancies

NCT07368478 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Malignancies

Interventions

DRUG: BC2027 for Injection

Sponsor

Biocity Biopharmaceutics Co., Ltd.